今年以来，美国特朗普政府多次对伊朗发出军事威胁，同时，持续强化在中东地区的军事部署，包括部 署"亚伯拉罕·林肯"号航母打击群等，进一步加剧地区紧张局势。 据央视新闻，当地时间1月31日，记者获悉，伊朗正在与美国"进行对话"。 美国总统特朗普称，"伊朗在跟我们谈，我们会看看能否达成一些协议，否则就拭目以待。" 另据新华社消息，伊朗总统佩泽希齐扬1月31日晚表示，对伊朗而言，通过外交途径解决分歧始终优先 于战争。"战争既不符合伊朗的利益，也不符合美国和整个地区的利益。" 来源：央视新闻、新华社 （文章来源：华夏时报） ...

值得关注的是，《熊出没·年年有熊》是熊出没IP系列电影的第12部作品，其中《熊出没·逆转时空》票 房为19.83亿元，为2024年动画片票房冠军，其前11部《熊出没》系列电影的累计票房也已经突破了83 亿元。 另外两部影片为《惊蛰无声》和《星河入梦》。前者由张艺谋执导，易烊千玺、朱一龙、宋佳等人主 演，由国家安全部指导创作，聚焦近年来较为少有的现代谍战犯罪题材。本片也是张艺谋导演作品近五 年来第四次进军春节档。《星河入梦》由王鹤棣、宋茜领衔主演，是韩延导演继2024年《我们一起摇太 阳》后再度征战春节档。 今年电影定档时间较往年稍晚。从《飞驰人生3》在12月26日官宣定档后，直到1月15日，《熊出没·年 年有熊》才姗姗来迟，此后多部影片接连官宣定档。 从目前定档的春节档影片看，类型涵盖剧情、喜剧、犯罪、动作、武侠、动画、奇幻、冒险等，题材广 泛，类型丰富。与去年类似，今年春节档影片也多围绕IP展开。 《飞驰人生3》是"飞驰人生"系列的第三部，依然由沈腾领衔的原班人马回归，韩寒继续担任导演。 《镖人：风起大漠》由著名武术指导袁和平担任导演，集结了包括吴京、谢霆锋、于适、此沙、李连杰 等在内的一众动作演员。影片改 ...

据新华社消息，美国总统特朗普30日称，伊朗希望同美国达成协议，他已向伊朗方面告知达成协议的最后期限。 特朗普当天在白宫签署一项行政令时回答媒体提问。被问及是否有达成协议的最后期限时，特朗普称已同伊方沟通，但没有透露具体日期，说"只有他们 自己知道"。 有记者问，如果伊朗不达成协议，美国是否要采取类似在委内瑞拉的军事行动。特朗普说，他"不想谈论任何与正在进行的军事行动有关的事情"，但同时 强调"我们在那里有一支非常强大的舰队"。 据环球时报报道，特朗普在椭圆形办公室举行的记者会上表示，"一支庞大的舰队正驶向伊朗，其规模甚至超过了我们部署在委内瑞拉附近的舰队……我 们将拭目以待。我可以肯定地说，他们确实想要达成协议"。 另据央视新闻消息，以色列国防军情报局局长什洛米·宾德尔于27日和28日分别与美国国防部、中央情报局及白宫官员会面，向美国提供了以色列掌握的 情报信息，其中包括伊朗恢复弹道导弹计划的相关信息。 据悉，以色列预计，美国总统特朗普在下令对伊朗发动袭击前，会先尝试各种谈判手段。 普京见了伊朗高官 俄罗斯总统新闻秘书佩斯科夫1月30日说，俄总统普京当天在克里姆林宫会见伊朗最高国家安全委员会秘书、最高领袖顾问 ...

不久前，记者接到群众爆料，国家土地督察北京局指出的9处违法违规至今不但没有被纠正，违规土地 上反而建起高楼。一场横跨十余年的土地出让纠葛，将一个关于规划、契约与纠错的故事推向台前。 1月29日，《华夏时报》记者在河北遵化市文礼东街南侧看到，一个名为依水·嘉和府的房地产项目工地 沉寂无声。褪色的铁皮门在风中微微摆动，围挡内的工地静止已久，地基坑洼处积着前几日未融化的积 雪，几座裸露着锈迹斑斑铁架的大楼如同被遗忘的雕塑。对面售楼中心大门紧锁，透过低矮的围墙，能 看到里面一个从未建成的高档小区雏形。对于北京东方依水源房地产开发有限公司（下称"依水源公 司"）而言，这片40余亩的土地纠纷是一场持续了十七年的漫长马拉松，而如今，结束的时刻似乎伴随 着法槌的敲响而来。 同一片土地的两条故事线 时间回溯至2008年，那是一个城市建设高歌猛进的年代。4月，遵化市政府土地收购储备中心与依水源 公司签订协议，将东沙河西岸这片土地出让给后者进行开发。随后经过招拍挂程序，依水源公司以约 1.44亿元的价格取得了国有建设用地使用权。在当时，这被视为一个拉动投资、提升城市形象的普通项 目。然而，波澜在平静的水面下暗生。记者根据报料人提供 ...

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at up to $18.5 billion, was met with unexpected market skepticism, leading to a significant drop in stock prices for both companies involved [2][4][7]. Group 1: Strategic Collaboration Details - CSPC Pharmaceutical Group announced a strategic partnership with AstraZeneca to co-develop innovative long-acting peptide drugs based on CSPC's drug delivery technology and AI discovery platform [3][4]. - The agreement includes a $1.2 billion upfront payment, up to $3.5 billion in research milestone payments, and $13.8 billion in sales milestone payments, along with a double-digit revenue share based on annual net sales [4][5]. - This deal surpasses the previous record of $11.4 billion set by Innovent Biologics and Takeda in 2025, marking a new high for outbound licensing in China's biopharmaceutical sector [4]. Group 2: Market Reaction and Concerns - Following the announcement, CSPC's stock fell by 9.82% to HKD 9.64 per share, while its closely related company, New Horizon Health, saw a drop of 15.72% [2][7]. - Analysts suggest that the market's negative reaction stems from concerns over the details of the deal and the companies' fundamentals, indicating that the perceived benefits may not align with the actual risks involved [7]. - The milestone payments are contingent on successful clinical trials and market performance, raising questions about the viability of CSPC's projects in a competitive landscape [7][8]. Group 3: Product and Competitive Landscape - The core asset in this collaboration is SYH2082, a long-acting weight management drug currently in Phase I clinical trials, targeting GLP-1R and GIPR receptors [8][9]. - The competitive landscape for GLP-1 drugs is intensifying, with major players like Eli Lilly and domestic companies rapidly advancing their own dual-target and multi-target drugs [9][10]. - CSPC's late entry into the clinical phase with SYH2082 presents challenges in efficacy differentiation and safety optimization, which will be critical for its future competitiveness [10]. Group 4: Financial Context and Implications - CSPC's decision to pursue this significant licensing deal comes at a time when its financial performance is under pressure, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [11]. - New Horizon Health stands to benefit from the upfront payment, which will help alleviate its cash flow issues as it anticipates a significant net loss in 2025 due to high R&D expenditures [12].

Core Insights - The ECMO market in China is undergoing a significant transformation, moving from foreign brand dominance to a surge in domestic alternatives driven by policy support, technological advancements, and increasing clinical demand [1][2][8] - The market size for ECMO in China is projected to reach 960 million yuan in 2024, growing to 3.71 billion yuan by 2030, with a compound annual growth rate of 25.2% from 2024 to 2030 [1][2] - The current ECMO penetration rate in China is low, with only one device per 280 million people, indicating substantial growth potential [1] Market Restructuring - Historically, foreign brands like Maquet, Medtronic, and Fresenius Kabi have controlled approximately 70% of the ECMO market, leading to high procurement costs for domestic medical institutions [2][3] - The price of foreign ECMO devices ranges from 1.5 million to 3 million yuan, with some high-end models costing up to 8 million yuan, creating a significant cost burden [2] - Recent policy changes, including the "Healthy China 2030" initiative and revised medical device regulations, have facilitated the entry of domestic companies into the market [2][3] Domestic Market Growth - Domestic ECMO devices are priced between 1.035 million and 1.5 million yuan, approximately 30% lower than imported devices, leading to a steady increase in market share [3] - By mid-2025, domestic ECMO devices are expected to capture over 30% of the market, with projections of reaching 35% by the end of 2025 [3] - Companies like Hanno Medical, Changzheng Medical, and Saiteng Medical are emerging as key players in the domestic market, with Changzheng Medical reporting significant sales and market presence [3][4] Technological Advancements - Changzheng Medical leverages technology from the China Aerospace Science and Technology Corporation, applying advanced control and simulation techniques to develop competitive ECMO products [4] - The market is shifting from a focus on individual device sales to comprehensive solutions that include equipment, consumables, and services [4] - The rise of third-party medical equipment leasing companies, which hold 20% of the market share, is providing flexible solutions for smaller hospitals [4] Challenges and Pain Points - Despite the growth opportunities, challenges such as reliance on imported components, high costs, and insufficient insurance coverage hinder the widespread adoption of ECMO technology [5][6] - The cost of a single ECMO treatment can reach 100,000 to 200,000 yuan, with consumables accounting for over 60% of the total cost, and many regions do not fully reimburse ECMO treatments [5] - The lack of standardized efficacy evaluation and varying treatment levels across institutions further complicates the market landscape [5][6] Policy and Future Outlook - Ongoing improvements in insurance policies are gradually incorporating ECMO treatments into reimbursement frameworks, which is expected to alleviate patient financial burdens and enhance treatment efficiency [7] - The application of ECMO is primarily in tertiary hospitals' intensive care and cardiac surgery departments, but advancements in technology and training are expected to broaden its use across various medical fields [7][8] - The push for better healthcare infrastructure in lower-tier hospitals, supported by government policies, is likely to expand the market for ECMO technology [8] - The ECMO industry is at a critical juncture, where overcoming core technological challenges and optimizing cost structures will be essential for achieving sustainable development and making ECMO a more accessible medical technology [8]

本报（chinatimes.net.cn）记者张玫 北京报道 2026年1月27日，华宸未来稳健添利债券的基金持有人开始投票决定，是否将最后的"独苗"转给富国基 金。 与此同时，在内蒙古股权交易中心，第一大股东华宸信托有限责任公司挂牌转让所持华宸未来基金40% 股权。此次挂牌价为480万元，而这已是该笔股权的第二次挂牌，价格较首次挂牌的1720万元大幅折价 逾七成。 一边是核心资产的剥离，一边是股权的艰难处置，华宸未来基金的生存状态已然亮起红灯。更加值得注 意的是，华宸未来基金已连续三年未能成功发行任何新基金，此次最后一只公募产品的管理权如果成功 转让，华宸未来基金将"无基可管"。 基金管理人变更较为罕见 基金管理人变更这一动作被业内称为"罕见"操作。通常情况下，若基金运营困难，基金管理人会选择直 接清盘而非变更管理人。此次变更被认为是"化解风险产品的主动选择"。 "通常情况下，基金公司没有公募产品还可依靠专户业务维持。但华宸未来基金资不抵债，显然不属此 列。更罕见的是最后这只产品没选择清盘，而是整体转让给富国。这在我印象中没有先例。"资深基金 研究人士王铁牛向《华夏时报》记者表示。 "独苗"基金要转让了 根 ...

文/张智 从企业规模来看，大型企业PMI继续高于临界点。大型企业PMI为50.3%，仍位于扩张区间，大型企业 支撑作用持续显现；中、小型企业PMI分别为48.7%和47.4%，比上月下降1.1个和1.2个百分点，景气水 平有所回落。 一个亮点是，高技术制造业持续领跑。高技术制造业PMI为52.0%，连续两个月位于52.0%及以上较高水 平，相关行业发展态势持续向好。装备制造业PMI为50.1%，保持在扩张区间。消费品行业和高耗能行 业PMI分别为48.3%和47.9%，景气水平有所回落。 企业预期保持乐观。生产经营活动预期指数为52.6%，继续高于临界点。从行业看，农副食品加工、食 品及酒饮料精制茶等行业生产经营活动预期指数连续两个月位于56.0%以上较高景气区间，相关企业对 近期行业发展信心较强。 编辑：徐芸茜 1月份，制造业采购经理指数（PMI）为49.3%，比上月下降0.8个百分点，但传统淡季下企业生产仍继 续扩张。 具体来看，生产指数为50.6%，高于临界点，制造业生产保持扩张；新订单指数为49.2%，市场需求有 所回落。从行业看，农副食品加工、铁路船舶航空航天设备等行业生产指数和新订单指数均高于 5 ...

Core Insights - The performance of A-share listed companies for 2025 is showing a "polarization" trend, with significant differences in industry prosperity affecting earnings, where some companies achieve substantial profit growth while others, particularly in real estate and photovoltaic sectors, face losses [2][10] Group 1: Earnings Reports - As of January 30, over 70 companies have disclosed their 2025 annual reports, with more than 2200 companies providing earnings forecasts, indicating a clearer market outlook [2][7] - Among the companies that have reported, 51 achieved year-on-year revenue growth, highlighting the resilience of profit growth [3][6] - The top three companies in revenue growth are Shouyao Holdings, Lier Technology, and Xiamen Tungsten, with revenue increases of approximately 120%, 82.97%, and 47.84% respectively [4][5] Group 2: Profit Growth - A total of 47 companies reported year-on-year growth in net profit, with Wohua Pharmaceutical and Lier Chemical showing particularly strong performance, with net profit increases of 162.93% and 122.33% respectively [6] - Wohua Pharmaceutical achieved a revenue of 0.817 billion with a net profit of 0.096 billion, while Lier Chemical reported a revenue of 9.008 billion and a net profit of 0.479 billion [6] Group 3: Earnings Forecasts - Approximately 900 out of 2200 companies that disclosed earnings forecasts are expected to see profit increases, indicating strong growth momentum in the A-share market [7][10] - Notably, over 60 companies anticipate net profit growth exceeding 500%, with 20 companies expecting over 1000% growth, showcasing robust development potential [7][10] - Ningbo Fubang stands out with an expected net profit increase of 3099.59% to 4379.43%, driven by rising silver prices and asset optimization [8][9] Group 4: Loss Predictions - A significant number of companies, particularly in the real estate and photovoltaic sectors, are expected to report losses, with major firms like China Fortune Land Development and Greenland Holdings forecasting losses of 16 billion to 24 billion and 16 billion to 19 billion respectively [10] - The photovoltaic sector is also heavily impacted, with companies like Tongwei and TCL Zhonghuan predicting losses of 9 billion to 10 billion and 8.2 billion to 9.6 billion respectively [10]

具体行情显示，现货白银价格自北京时间23:00开始加速下滑，凌晨02:40左右跌至盘中低位每盎司74.31美元，跌幅最大时超过36%。截至收盘，现货白银 下跌26.42%报85.259美元/盎司。 据智通财经报道，周五（1月30日）纽约时段，国际贵金属价格大幅跳水，其中现货白银一度跌超36%，黄金最高跌超12%。 现货黄金价格也几乎在同一时间跌至每盎司4683.04美元的日内低位，跌幅最高时超过12%。截至收盘，现货黄金下跌9.25%报4880美元/盎司。 Evercore ISI副董事长Krishna Guha称，市场正在按"鹰派沃什"进行交易，"沃什的提名有助于稳定美元，并降低美元持续走弱的单边风险，从而挑战'货币 贬值交易'的逻辑——这也是金银大幅下跌的原因。" 特朗普提名凯文·沃什 为下任美联储主席 据央视新闻报道，美国总统特朗普30日提名美联储前理事凯文·沃什为下任美联储主席，这一提名还需获得参议院批准。 沃什2006年加入美联储，是当时最年轻的美联储理事。在美联储任职期间，沃什持鹰派货币政策立场，但近年转向支持特朗普的关税政策及加快降息立 场。 值得一提的是，特朗普在首个总统任期内提名鲍威尔为美联 ...